https://www.biopharmawatch.com/news/INO/inovio-fda-accelerated-approval-voceryq-rrp BiopharmaWatch en 2026-10-30T22:01:00.000Z INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) https://www.biopharmawatch.com/news/ACET/adicet-bio-inducement-grant-nasdaq-listing-rule BiopharmaWatch en 2026-10-30T21:38:00.000Z Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inducement-grant-new-employee BiopharmaWatch en 2026-10-30T21:15:00.000Z Actinium Pharmaceuticals Announces Inducement Grant to New Employee https://www.biopharmawatch.com/news/ANVS/annovis-bio-nyse-listing-notice BiopharmaWatch en 2026-10-30T21:00:00.000Z Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE https://www.biopharmawatch.com/news/ACH/accendra-health-receives-continued-listing-standard-notice-nyse-regarding-market BiopharmaWatch en 2026-10-30T20:45:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/MTD/mettlertoledo-investor-conferences-november-2023 BiopharmaWatch en 2026-10-30T20:30:00.000Z Mettler-Toledo International Inc. to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inducement-grants-october-2026 BiopharmaWatch en 2026-10-30T20:30:00.000Z PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARAY/accuray-inducement-award-nasdaq-rules BiopharmaWatch en 2026-10-30T20:10:00.000Z Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules https://www.biopharmawatch.com/news/UHS/universal-health-services-presentation-ubs-conference BiopharmaWatch en 2026-10-30T20:09:47.000Z Universal Health Services, Inc. to Present at The UBS Global Healthcare Conference https://www.biopharmawatch.com/news/GILD/gilead-sciences-investor-conferences-november-december-2026 BiopharmaWatch en 2026-10-30T20:05:00.000Z Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-upcoming-conference-presentations BiopharmaWatch en 2026-10-30T20:05:00.000Z Tandem Diabetes Care Announces Upcoming Conference Presentations https://www.biopharmawatch.com/news/RVTY/revvity-board-declares-quarterly-dividend-20261030 BiopharmaWatch en 2026-10-30T20:05:00.000Z Revvity Board Declares Quarterly Dividend https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261030 BiopharmaWatch en 2026-10-30T20:05:00.000Z TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/DYAI/dyadic-report-q3-2026-financial-results-conference-call BiopharmaWatch en 2026-10-30T20:05:00.000Z Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-inducement-grants-october-2026 BiopharmaWatch en 2026-10-30T20:01:00.000Z Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PHG/philips-launches-hypervue-integrated-system-cathlab BiopharmaWatch en 2026-10-30T20:00:00.000Z Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab https://www.biopharmawatch.com/news/SRXH/srx-global-balance-sheet-share-buyback-update BiopharmaWatch en 2026-10-30T19:16:00.000Z SRX Global Provides Update on Balance Sheet and Share Buyback https://www.biopharmawatch.com/news/RVMD/revolution-medicines-excellence-client-partnership-award BiopharmaWatch en 2026-10-30T16:00:00.000Z Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award" https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-1-4-reverse-stock-split BiopharmaWatch en 2026-10-30T14:30:00.000Z Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-avlayah-prix-galien-award BiopharmaWatch en 2026-10-30T13:30:00.000Z Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-plans-pivotal-trial BiopharmaWatch en 2026-10-30T13:10:00.000Z NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-castle-creek-merger BiopharmaWatch en 2026-10-30T13:09:00.000Z Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-rna-splicing-adc-payload-strategy BiopharmaWatch en 2026-10-30T13:05:00.000Z Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-prix-galien-award-2026 BiopharmaWatch en 2026-10-30T13:01:00.000Z Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases https://www.biopharmawatch.com/news/ALPS/alps-group-shareholder-approval-consolidation-capital-increase BiopharmaWatch en 2026-10-30T13:00:00.000Z Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association https://www.biopharmawatch.com/news/BGLC/bionexus-launches-new-corporate-website BiopharmaWatch en 2026-10-30T13:00:00.000Z BioNexus Launches New Corporate Website with Expanded Business and Investor Resources https://www.biopharmawatch.com/news/FEMY/femasys-appoints-john-moorhead-board-directors BiopharmaWatch en 2026-10-30T13:00:00.000Z Femasys Appoints John Moorhead to Board of Directors https://www.biopharmawatch.com/news/VTRS/viatris-tender-offer-acquire-pacira-biosciences BiopharmaWatch en 2026-10-30T12:40:00.000Z Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. https://www.biopharmawatch.com/news/MBRX/moleculin-completes-dosing-miracle-trial BiopharmaWatch en 2026-10-30T12:40:00.000Z Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 https://www.biopharmawatch.com/news/DARE/dare-bioscience-grant-funding-dare-larc1-development BiopharmaWatch en 2026-10-30T12:32:00.000Z Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum https://www.biopharmawatch.com/news/CDT/cdt-equity-hhs-regulatory-development-peptides BiopharmaWatch en 2026-10-30T12:32:00.000Z CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides https://www.biopharmawatch.com/news/MSA/msa-safety-declares-quarterly-dividend-20261030 BiopharmaWatch en 2026-10-30T12:30:00.000Z MSA Safety Declares Quarterly Dividend https://www.biopharmawatch.com/news/NVNO/envveno-medical-q3-2026-financial-results-tavve-study BiopharmaWatch en 2026-10-30T12:30:00.000Z enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-november-2026 BiopharmaWatch en 2026-10-30T12:30:00.000Z PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-educational-resources-classic-cah BiopharmaWatch en 2026-10-30T12:30:00.000Z Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-phase-1b-study-advanced-cancer BiopharmaWatch en 2026-10-30T12:30:00.000Z Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-reports-q3-2026-results BiopharmaWatch en 2026-10-30T12:30:00.000Z IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IART/integra-lifesciences-cns-2026-annual-meeting BiopharmaWatch en 2026-10-30T12:30:00.000Z Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-sitc-2026-presentation BiopharmaWatch en 2026-10-30T12:30:00.000Z Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting https://www.biopharmawatch.com/news/OGN/organon-announces-quarterly-dividend-20261030 BiopharmaWatch en 2026-10-30T12:25:00.000Z Organon Announces Quarterly Dividend https://www.biopharmawatch.com/news/STXS/canon-stereotaxis-robotic-electrophysiology-collaboration BiopharmaWatch en 2026-10-30T12:03:00.000Z Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology https://www.biopharmawatch.com/news/VOR/vor-bio-reports-q3-2026-results BiopharmaWatch en 2026-10-30T12:00:09.000Z Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-financial-results-september-2026 BiopharmaWatch en 2026-10-30T12:00:00.000Z Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress https://www.biopharmawatch.com/news/PROF/profound-medical-cook-medical-partnership-tulsa-pro BiopharmaWatch en 2026-10-30T12:00:00.000Z Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-30T12:00:00.000Z Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-therapeutic-efficacy-study BiopharmaWatch en 2026-10-30T11:50:00.000Z Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results https://www.biopharmawatch.com/news/ABBV/abbvie-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-30T11:46:00.000Z AbbVie Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-first-commercial-agreement-clia-strategy BiopharmaWatch en 2026-10-30T11:45:00.000Z Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue https://www.biopharmawatch.com/news/OABI/omniab-reports-q3-2026-results BiopharmaWatch en 2026-10-30T11:40:00.000Z OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/IMNM/immunome-ema-validation-varegacestat-desmoid-tumors BiopharmaWatch en 2026-10-30T11:30:00.000Z Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors https://www.biopharmawatch.com/news/BRVE/braveheart-bio-aha-scientific-sessions-2026 BiopharmaWatch en 2026-10-30T11:30:00.000Z Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/BRVE/braveheart-bio-webinar-hcm-spotlight-november-2026 BiopharmaWatch en 2026-10-30T11:30:00.000Z Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026 https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q1-fy27-update BiopharmaWatch en 2026-10-30T11:05:00.000Z Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update https://www.biopharmawatch.com/news/ALKS/alkermes-phase-2-study-alks-7290-mdd BiopharmaWatch en 2026-10-30T11:00:00.000Z Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) https://www.biopharmawatch.com/news/AZN/astrazeneca-results-9m-q3-2026 BiopharmaWatch en 2026-10-30T11:00:00.000Z AstraZeneca results: 9M and Q3 2026 https://www.biopharmawatch.com/news/AGIO/agios-mitapivat-pdufa-extension-february-2027 BiopharmaWatch en 2026-10-30T11:00:00.000Z Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-patent-portfolio-fda-submission BiopharmaWatch en 2026-10-30T11:00:00.000Z Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-approval-preservative-free-ketamine BiopharmaWatch en 2026-10-30T11:00:00.000Z NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-altitude-ad-trial-results BiopharmaWatch en 2026-10-30T11:00:00.000Z Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-november-investor-conferences BiopharmaWatch en 2026-10-30T11:00:00.000Z Syndax Announces Participation in November Investor Conferences https://www.biopharmawatch.com/news/REGN/regeneron-reports-q3-2026-results BiopharmaWatch en 2026-10-30T10:30:00.000Z Regeneron Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261030 BiopharmaWatch en 2026-10-30T10:00:00.000Z IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-investor-conferences-2026 BiopharmaWatch en 2026-10-30T10:00:00.000Z Kestra Medical Technologies to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-30T10:00:00.000Z BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance https://www.biopharmawatch.com/news/RGEN/repligen-announces-1-billion-convertible-notes-transaction BiopharmaWatch en 2026-10-30T10:00:00.000Z Repligen Announces $1 Billion Private Convertible Senior Notes Transaction https://www.biopharmawatch.com/news/EVAX/evaxion-prix-galien-award-ai-immunology BiopharmaWatch en 2026-10-30T08:00:00.000Z Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution https://www.biopharmawatch.com/news/SNY/sanofi-q3-2026-sales-growth-guidance-upgraded BiopharmaWatch en 2026-10-30T06:30:00.000Z Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded https://www.biopharmawatch.com/news/SIBN/si-bone-presents-ubs-global-healthcare-conference-2026 BiopharmaWatch en 2026-10-29T21:43:00.000Z SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026 https://www.biopharmawatch.com/news/TLX/telix-general-meeting-acquisition-itm BiopharmaWatch en 2026-10-29T21:15:30.000Z Telix Notice of General Meeting, Proxy Form and Online Guide https://www.biopharmawatch.com/news/TMDX/transmedics-upcoming-investor-conferences BiopharmaWatch en 2026-10-29T21:01:00.000Z TransMedics to Present at Upcoming Investor Conferences